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State of tumor microenvironment (TME) is closely linked to regulation of tumor growth and progression affecting the final
outcome, refractoriness, and relapse of disease. Interactions of tumor, immune, and mesenchymal stromal/stem cells (MSCs)
have been recognized as crucial for understanding tumorigenesis. Due to their outstanding features, stem cell-like properties,
capacity to regulate immune response, and dynamic functional phenotype dependent on microenvironmental stimuli, MSCs have
been perceived as important players in TME. Signals provided by tumor-associated chronic inflammation educate MSCs to alter
their phenotype and immunomodulatory potential in favor of tumor-biased state of MSCs. Adjustment of phenotype to TME and
acquisition of tumor-promoting ability byMSCs help tumor cells in maintenance of permissive TME and suppression of antitumor
immune response. Potential utilization of MSCs in treatment of tumor is based on their inherent ability to home tumor tissue that
makes them suitable delivery vehicles for immune-stimulating factors and vectors for targeted antitumor therapy. Here, we review
data regarding intrusive effects of inflammatory TME onMSCs capacity to affect tumor development throughmodification of their
phenotype and interactions with immune system.
1. Introduction
Establishment of the tumor microenvironment (TME) is
the most important condition for the sustention of tumor
growth. Firstly, formation of TME has been characterized in
primary tumors, while today it is clear that creation of tumor-
supporting niches at distant sites of the body is required
for metastasis progression [1]. Namely, TME plays crucial
role in each step of tumor development: oncogenic transfor-
mation/initiation, angiogenesis, immune surveillance escape,
metastasis, survival of circulating tumor cells in blood, tumor
cell stemness, and resistance to radio- and chemotherapy. In
order to foster tumor propagation at distant niches, tumor
cell-derived factors act in systemic manner, not only locally,
thus providing spreading and recurrence of disease [2].More-
over, supporting a dormancy of tumor cells, TME can provide
survival of clinically inconspicuous and hardly detectable
metastasis in the body for long time, which is implicated
in appearance of relapse. Besides tumor cells, TME includes
endothelial cells, fibroblasts, mesenchymal stromal/stem cells
(MSCs), and various immune cells, which are together with
cytokines and growth factors embedded in tumor stroma
endowedwith specific physical (oxygen pressure) and biome-
chanical cues [3].Thus, understanding of themultiplex visage
of TME composition is important not only in investigation of
molecular basis of cancer disease, but also in bioengineering
of tumor tissue for investigation of disease development, as
well as for drug efficacy and safety testing [4]. Reciprocal
communication between cells and their microenvironment is
important not only for normal tissue development and home-
ostasis, but also for tumor growth and progression [5]. After
many years of investigations, multifaceted roles of TME are
today understood as consequence of its active and dynamic
composition. It could be speculated that the active nature of
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TME is actually reflection of the dynamic phenotype or plas-
ticity of cellular compartments within [6]. Heterogeneity of
tumor cell population in tumor tissue is well known, but now
it is clear that such heterogeneity may be mastered and
modified by nontumor cells in TME. This interplay between
tumor and nontumor cells in TME is bidirectional. Obliga-
tory condition for tumor development is evasion of antitumor
immune response. Tumor cells have various different instru-
ments to avoid destruction by immune system and impor-
tantly to control the balance of inflammation in TME and
behavior of immune cells. As third player, MSCs have
received great attention in cancer research due to their out-
standing properties, tumor-homing ability, dynamic pheno-
type, and immunoregulatory activity [7]. It looks like the
evolution of tumor includes adjustment of complete TME.
Importantly, TME shapes phenotypes and functions ofMSCs
and immune cells assigning them tumor-supportive roles.
Recently, it has been proposed that epigenetic modifica-
tions (histone modifications, changes in expression of DNA
methyltransferases, and factors of chromatin modification
and microRNA) in tumor as well as in stromal compartment
of TME can appear during reprogramming process and
contribute to the tumor progression [8–10].
2. Persistence of Chronic Inflammation and
Hypoxia in TME
Healing of normal damaged tissue includes inflammatory
phase which precedes proliferation of resident epithelial
and mesenchymal cells and tissue remodeling. Inflammatory
phase is limited up to 14 days and include recruitment
and infiltration of neutrophils, macrophages, and lympho-
cytes which play crucial role in secretion of inflammatory
cytokines, growth factors, and chemokines involved in resi-
dent progenitor cells activation and tissue regeneration and
repair [11]. The inflammatory response is finalized by elimi-
nation of harmful agents and repair of tissue damage through
the differentiation of resident or recruited stem/progenitor
cells or by forming scar made of connective tissue to save
tissue integrity [12].
Contrary to normal tissue, when prolonged inflammation
occurred, “wounds that do not heal” or “overhealingwounds”
[13, 14] can cause development of tumor tissue [2]. Wound
healing in normal and tumor tissue refers to the engagement
of growth and differentiation processes in epithelial as well
as stromal components of tissue. In contrary to normal tissue
homeostasis and repair, development of neoplastic tissue is
characterized by loss of control of many cellular, molecular,
and biochemical processes [9].
Chronic inflammation is involved in pathogenesis in
many human diseases, while in some circumstances it can
contribute to oncogenesis as well [15]. State of chronic inflam-
mation and infiltration of immune cells in TME of solid
tumors had been proposed in 19th century by German patho-
logist Rudolf Virchow [16] and today it is known that tissue
injury and chronic inflammation are important risk fac-
tors for tumor development. Besides deranged apoptosis,
response to growth signals, necessity for growth factors,
angiogenesis, replicative potential, and invasion of tumor
cells, inflammation is assigned as the seventh hallmark of can-
cer [17, 18]. Therefore, it is very important to identify cellular
and humoral factors which are responsible for resolution of
inflammation in normal tissue repair process as well as in
development of malignant transformation [19].
One of the proposed contributors and a possible causer
of inflammation in tumor is low oxygen (O
2
) concentration
(hypoxia). It is known that initial (over)growth of trans-
formed cells is followed by insufficient angiogenesis, which
results in hypoxia (partial pressure of O
2
1.1–1.3%) in themid-
dle of tumor tissue. In this region, many tumor cells undergo
necrosis, while the peripheral regions survive and adapt to
hypoxia thanks to the hypoxia-inducible factor 1 (HIF-1)
dependent gene expression, where transformed cells become
more glycolytic [12, 20]. In general, swelling tissue forces cells
to consume oxygen to survive hard conditions in inflamed
regions, thus creating their hypoxic nature. It looks that
cancer stemcells aremore adapted to hypoxic conditions than
differentiated tumor cells, due to their quiescence and low-
energetic demands [21]. However, because tumor cells are not
engaged in tissue homeostasis, tumor-associated hypoxia is a
pathophysiologic state [22–24], caused by corrupted micro-
circulation which became a central issue and impediment
in tumor biology and treatment, since hypoxic regions show
resistance to the radio- and chemotherapy thus being nega-
tive prognostic and predictive indicators [25, 26]. Moreover,
it has been demonstrated that the hypoxia and HIF-1 stabi-
lization may lead to reduced activity of macrophages, which
become unable to phagocyte tumor cells. Also, the HIF-1
stimulates production of CD47 in tumor cells, a cell surface
protein that enables tumor cells to avoid destruction by
macrophages [27].
Activities of hypoxia and inflammation in tumor are
intertwined at the molecular and cellular level [28, 29].
Importantly, reacting to hypoxia and HIF-1 activation, tumor
and normal stromal cells can express alarmin receptors which
bind alarmins released by necrotic cells in tumor tissue.
Signaling triggered by alarmin receptor leads to the activation
of nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-𝜅B) and expression of proinflammatory genes,
thus contributing to tumor progression. NF-𝜅B activation by
HIF-1 triggered by hypoxia or accumulated cytosolic reactive
oxygen species lead to production of inducible proinflamma-
tory enzymes: inducible 5-lipoxygenase (5-LOX), NADPH-
oxidases (NOX), inducible nitric oxide synthase (iNOS),
inducible cyclooxygenase (COX2), and inducible heme-
oxygenase-1 (HO-1) [12]. Considering that activation of the
NF-𝜅B by hypoxia and increment of various cytokines pro-
duction has been observed in bone marrow MSCs [30], it
is plausible to speculate that tumor-associated hypoxia can
stimulate production of tumor-supporting factors in MSCs
in NF-𝜅B-dependent manner.
On the other hand, unavoidable hypoxia in TME can be
fertile ground for generation of regulatory immune cells, such
as regulatory T cells (Treg) and myeloid-derived suppressor
cells (MDSCs) in tumor [31]. Importantly, HIF-1 is pertinent
factor involved in regulation of metabolic commitment of
immune cells, immunometabolism, thus controlling their
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activation, proliferation, and effector functions [32]. Com-
plexity of metabolic configuration of immune cells is related
to their energy demands, synthesis of biomolecules, and
subsistence [33]. However, it has been demonstrated that
HIF-1 controls generation of tolerogenic immune cells in
TME, such as Treg [34], MDSCs [35], and tumor-associated
macrophages (TAMs) [36]. These evidences indicated that
hypoxia could be regulator of inflammation in TME, by con-
trolling metabolic state of immune cells. Although hypoxia
is known as regulator of stem cell metabolism [37], there
is scant data about influence of hypoxia on immune status
and activities of MSCs and this issue should be further
explored because it may be expected that hypoxia governs
immunosuppressive properties of MSCs. These answers can
help to better understand immune properties of MSCs [38]
and their participation in pathogenesis of cancer.
3. MSCs: Recruitment and Functions in TME
Mesenchymal stromal/stem cells (MSCs) are widely dis-
tributed in TME, where they communicate with other cells
and participate in the tumor development. Moreover, besides
myofibroblasts, pericytes, and hematopoietic cell-derived
fibrocytes, MSCs are also identified as possible cell origin of
tumor-associated fibroblasts (TAFs). Because of heterogene-
ity within cells in the TAF population, their unresolved ori-
gin, many intermediate populations occurring during their
context-specific lineage commitment, and cellular plasticity
[39–41], there is still no consensus in the literature regarding
exactly defined phenotype and function of TAFs in TME.
In this part, we will discuss MSCs potential to respond to
various TME-derived stimuli, adapting their recruitment to
the tumor sites, phenotype, and functional properties.
As mentioned above, MSCs contribute to maintenance of
normal tissue homeostasis, while today it is clear that these
cells can influence tumor development.Namely,MSCs,which
have been recently assigned as “medicinal signaling cells” [41]
or “ambulatory cells” [42], have capacity to home sites of
inflammation, manifest immunosuppressive properties, and
differentiate into various cell types. For the same reasons,
MSCs have received great attention in cancer research.
It has been proposed that normal MSCs (N-MSCs) and
tumor MSCs (T-MSCs), although sharing similar phenotype
properties, could have different influence on tumor devel-
opment, demonstrating supportive role of T-MSCs in tumor
growth [43, 44]. Aforementioned data indicated conspicuous
importance of TME not only in tumor development, but
also in cancer recurrence and poor prognosis of patients.
Moreover, it has been shown that expression of mesenchymal
genes in tumor cells and mesenchymal signature in cancer
transcriptome are related to aggressiveness of cancer [45].
Also,molecular profiling of stromal cells from various human
tumors can provide significant diagnostic information [46].
It has been accepted that MSCs participate in each step
of tumor development: evasion of immune surveillance,
promotion of tumor angiogenesis, resistance to chemother-
apeutics, invasion and metastasis, and induction of stem-like
properties in tumor cells [43].
MSCs are implicated in tumor cells maintenance and
immunosurveillance evasion creating selective pressure for
tumor cells which escape antitumor immune response and
conditioning tumor progression [47]. This selective pressure
has been also found to be key factor for acquisition of neo-
antigens by tumor cell. Evasion of immune attack by tumor
cells is caused by their abilities to edit neoantigens unrecog-
nizable by adaptive immune system, acquire the resistance
to apoptotic/necrotic mechanisms, and suppress the adaptive
and innate immune response [39, 40, 48].
However, as context-dependent activation of stromal
cells has been demonstrated in healing of normal tissue,
recruitment and activity of stromal cells in tumors look to be
subordinated by TME circumstances. It is likely that tumor-
associated inflammation, whether it precedes or follows
tumor development, is part of the normal response to injury
and infection that has been converted by tumor cells to their
advantage [16].
Capacity of MSCs to regulate immune response is major
advantage for their use in cell-based therapies and tissue engi-
neering. However, this feature is not constitutive property of
MSCs, and it is important to note that microenvironment
stimuli can shape and modify immunosuppressive potential
of MSCs. Therefore, various factors can trigger different
immune status and activity ofMSCs, leading to stimulation or
suppression of immune response [49–51]. However, mecha-
nisms involved in the regulation of immunological properties
of MSCs are still not clearly understood.
Due to abundance of various factors and infiltrated
immune cells in TME, it is justifiable to speculate on signifi-
cance of interactions between MSCs and immune cells in the
context of tumor development. In case of solid tumors, it has
been described that heterogenic population of neoplastic cells
collaborates withMSCs and immune cells, forming a “vicious
triangle” [46] ormaybe “vicious circle” of tumor development
(Figure 1).
On the basis on previous data, where the C-X-C
chemokine receptor type 4 (CXCR4)/stromal-derived factor-
1 (SDF-1) (or CXCL12) has been shown as major axis impli-
cated in regulation of hematopoietic stem cells recruitment
and retention in bone marrow stroma, it has been proposed
that the same axis is involved in regulation of MSC recruit-
ment to tumors [52, 53]. Also, it has been demonstrated that
tumor cells which express CXCR4 home bone marrow and
that SDF-1 attracts MSCs from bone marrow or other sites in
body to tumor tissue [54].Moreover, it has been reported that
soluble factors of tumor cells can induce secretion of SDF-1
by MSCs and enhance their motility [55]. However, precise
role of SDF-1 in ability of MSCs to home tumor tissue is
not completely elucidated, as some studies have showed that
tumor cells produce no SDF-1.Moreover it has been proposed
that macrophage migration inhibitory factor (MIF) is major
regulator of MSC migration toward tumors. There has been
observed physical interaction between MIF and CXCR2,
CXCR4, and CD74, although only CXCR4 is dominant
receptor recognized by MIF in context of tumor homing.
Also, it has been shown that activation of the Mitogen-
Activated Protein Kinases (MAPK) pathway in MSCs has
been necessary for tumor homing [56].














Figure 1: Tumor microenvironment (TME) as a fertile ground for dynamic cell phenotype and function. Composition of TME implies
immediate vicinity of mesenchymal stromal/stem cells (MSCs), tumor-associated fibroblasts (TAFs); immune cells: macrophages (MB),
regulatory T cells (Treg), myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, dendritic cells (DCs), monocytes, neutrophils,
T lymphocytes, B cells, and heterogenic population of tumor cells. Reciprocal communication within cellular compartment is accomplished
through the paracrine network.
As final step of the diapedesis, migration of bone marrow
MSC toward tumor has been described to be dependent on
matrix metalloproteinases (MMPs) expression in MSCs [53].
It has been observed that MSC tropism toward glioma cells is
regulated by MMP-1-activated CXCR4/SDF-1 axis [57]. Also,
tropismof adipose tissueMSCs toward brain tumors has been
demonstrated by Feng et al., 2014 [58]. Interestingly, in this
study, it has been reported that hypoxia increasesmotility and
tropism of MSCs toward glioblastoma in vitro and in vivo,
without change in their differentiation toward TAFs.
It could be speculated that retention of MSCs in the TEM
of breast cancer is also regulated by the presence of hypoxia in
various tumor zones. It has been shown that hypoxia induced
HIF-1 stabilizationmediates bidirectional paracrine signaling
between breast cancer cells andMSCswhich stimulates breast
cancer metastasis [59].
On the other hand, MSC niche can be target for dissem-
inated tumor cells. The human bone marrow can become
populated with tumor cells of breast cancer patients [60], as
well as prostate cancer [61]. It has been demonstrated that
disseminated tumor cells inhabiting bone marrow stroma
can lead to reduction of hematopoiesis and level of SDF-1.
Moreover, it has been found that disseminated tumor cells
express markers of hematopoietic cells presented in bone
marrow, thus mimicking microenvironmental marker pat-
tern expression, which complicate detection of tumor cells
and may contribute to inefficiency of therapeutics [61]. Also,
CXCR4/SDF-1 signaling has been shown to be involved in
the homing and proliferation of leukemia cells in acute
myeloid leukemia (AML), chronic myeloid leukemia (CML),
and other hematologic malignancies. It is important to note
that CD44 and very late antigen-4 (VLA-4, 𝛼4𝛽1-integrin)
receptor expressed by leukemia cells govern their adhesion
to bone marrow stromal cells in the niche and consequent
induction of antiapoptotic effects that support leukemia cell
survival. Furthermore, bone marrowMSCs have been shown
to up-regulate the secretion of several inflammatory factors
(interleukin- (IL-) 6, vascular endothelial growth factor
(VEGF), SDF-1, and tumor necrosis factor-𝛼 (TNF-𝛼)) as a
result of their direct interaction with myeloma cells, which
in turn promote supportive role of TME in undisturbed
survival, growth, and development of multiplemyeloma [62].
Moreover, it has been demonstrated thatCD138-myeloma
cells, which have elevated expression of SDF-1, induce higher
stiffness in MSCs from multiple myeloma patients than in
normal MSCs through the induction of SDF-1/CXCR4/AKT
signaling [55].
In addition, the link between obesity and tumor for-
mation has been accepted, where tumor-supporting role of
inflammation, adipokines, and chemokines has been sug-
gested. It has been found that adipose tissue MSCs con-
tribute to tumor-promoting state of TME, through increased
secretion SDF-1, VEGF, chemokine ligand 5 (CCL5), platelet-
derived growth factor D (PDGF-D), and TGF-𝛽 in response
to presence of tumor cells. Moreover, hypoxia localized in
adipose tissue, has been shown to be associated with elevated
levels of proinflammatory cytokines, TNF-𝛼, and IL-6, which
are known as important factors in tumorigenesis [63].
4. The Issue of Tumor-Associated
Fibroblast (TAF)
In the literature, the term of TAFs is commonly used for cell
population actively participating in TME constitution and
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cancer progression, and despite their poor defined identity, it
covers a heterogeneous population of stromal cells displaying
various phenotypes. Although fibroblasts aremost frequently
recognized resident cell type in tumor stroma, they possess
very dynamic context-dependent phenotype and functions.
Recently, three states of fibroblasts in context of TME
have been proposed: resident fibroblasts, tumor permissive
or suppressive “primed” fibroblasts, and tumor-promoting
“activated” fibroblasts [64]. However, it has been suggested
that TAFs can originate from recruited or resident fibroblasts,
stem/progenitor, or immune cells deriving from surrounding
tissue or bonemarrow.Also, TAFs can ensue from tumor cells
in the process of the epithelial-to-mesenchymal transition
(EMT). Within stem/progenitors compartment, MSCs are
proposed as one of potential candidates for origin of TAFs.
Namely, MSCs can acquire myofibroblastic phenotype of
TAFs [46, 65]. After activation and differentiation intomyofi-
broblasts, TAFs produce several mesenchymal proteins such
as fibroblast-specific protein (FSP-1), fibroblast-activating
protein (FAP), vimentin, and 𝛼-smooth muscle actin (𝛼-
SMA). As expression of 𝛼-SMA, FSP1, FAP, chondroitin
sulfate proteoglycan (NG2), and PDGFR-𝛽 is also common
for normal fibroblasts, it is proposed that bulk population of
TAFs consist of two subpopulations: fibroblasts and myofi-
broblasts [66]. Also, it has been described that bone marrow
derived cells differentiate into TAFs which secrete large
amount of extracellular matrix (ECM) components, but also
mediators of tumor cells invasion such as metalloproteinase-
13 [67].
During normal tissue repair, activated fibroblasts migrate
toward inflamed region, proliferate, and differentiate into
highly contractile myofibroblasts. Presence of various growth
factors, such as TGF-𝛽, but also mechanical properties of
extracellular matrix can master differentiation of myofibrob-
lasts [9].
In tissue repair process, transition of fibroblast intomyofi-
broblast is the most important physiological event, while its
disruption leads to fibrosis and eventually to tumorigenesis.
Several studies have demonstrated that differentiation of
stem/progenitor cells into myofibroblasts is regulated by
TGF-𝛽. It has been demonstrated that TGF-𝛽 regulate initial
as well as later phase of myofibroblast differentiation of
adipose tissue MSCs towards stationary myofibroblasts [68].
Differentiation of adipose tissue MSCs into TAFs, induced
by breast tumor cells-derived TGF-𝛽, is regulated through
Smad3 signaling [65]. Moreover, it has been demonstrated
that adipose tissue-derived MSCs develop contractile myofi-
broblastic phenotype after treatment with TGF-𝛽, increasing
expression of 𝛼-SMA and ECM proteins, such as collagen
and fibronectin. Interestingly, in this study, it has been
described that other tissue factors, such as fibroblast growth
factor (FGF), induce redifferentiation of myofibroblasts into
fibroblast-like cells [69].
Also, it has been demonstrated that exosomes secreted by
prostate cancer cells induce subsequent phenotype changes
of bone marrow MSCs, inhibiting their adipogenic and
promoting myogenic differentiation through stimulation of
𝛼-SMA expression. In this study, the role of TGF-𝛽 in
exosome-mediated effects on MSC differentiation has been
confirmed, while MSC-derived myofibroblasts have been
shown to possess tumor-promoting activity [70].
However, nondistinctive origin of TAFs indicates that
TAFs may be defined as dynamic and transiently state of
fibroblast-like cells, rather than certain phenotype. TAFs can
be retained in TME for long time and it may be speculated
that TME,with all its unsteady elements, contributes tomain-
tenance of TAF state [71].Moreover, it has been proposed that
maintenance of TAF state in TME could be ensured through
epigenetic alteration in tumor-associated stromal cells. It has
been observed that tumor-associated stromal cells promote
epithelial tumor cells growth, by activated Wnt/𝛽-catenin
signaling. Also, overexpression of chromatin remodeling pro-
tein Hmga2, an epigenetic regulator in the stroma, induces
tumorigenic lesions in the neighboring epithelium in a Wnt-
dependent manner [72].
According to these data, it is clear that TME may con-
tribute to reorganization of lineage commitment of various
cells, especially of MSCs through modulation of their dif-
ferentiation, indirect/direct transdifferentiation, and/or cell
fusion of MSCs with tumor cells [73]. Therefore it can be
speculated that TAF may present example of tumor-biased
and redirected phenotype of MSCs.
5. TAFs Ensure Tumor Enhancing
Inflammation and Immunosuppression
There are many evidences of the proinflammatory role of
TAFs. It has been observed that TAF from human colorectal
liver metastasis in response to TNF-𝛼 and consequent acti-
vation of NF-𝜅B produce elevated level of proinflammatory
cytokine IL-8 [74]. Additionally, microarray results demon-
strated high expression of a number of factors such asCXCL2,
IL-6, IL-1𝛽, CXCL1, CXCL5, COX-2, MMP12, MMP3, and
osteopontin (OPN) in TAFs founded in skin, mammary,
and pancreatic tumors. This inflammatory signature of TAFs
promoted macrophage recruitment, neovascularization, and
tumor growth [75, 76]. Additionally it has been observed
that binding of IL-1𝛼 produced by pancreatic tumor cells
to IL-1 receptor 1 on TAFs strongly induce production of
inflammatory factors by TAFs, contributing to persistence of
inflammatory TME [75]. During early tumorigenesis, TAFs
have been shown to produce many proinflammatory medi-
ators which can be further stimulated by factors produced
by resident immune cells. Also, TAFs have been observed
to secrete CCL2 and recruit macrophages in TME. On the
other side, TGF-𝛽-producing TAFs inhibit natural killer
(NK) cell and cytotoxic T lymphocytes (CTL) activation,
while stimulating generation of Treg [16].
Additionally, in comparison to normal fibroblasts, TAFs
have been shown to express coregulatory molecules, two
ligands of programmed death (PD) receptor, PD-L1 and PD-
L2, and strongly suppressed proliferation of T lymphocytes.
These results indicated that TAFs collaborate with tumor cells
and TME in order to establish immunosuppressive milieu
and facilitate tumor evasion from immune system [77, 78].
Therefore, it is justifiable to view TAFs as example of
“extended phenotype” that was conceived byDawkins in 1982
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[79]. TAFs can serve as an example of how TME educate
nontransformed and genetically stable stromal cells to sup-
port tumor growth [71, 80]. In similar manner, TME can
educate MSCs. TAF represent polarized cell type, which in
dependence of type of microenvironmental cues can acquire
phenotype I (antitumorigenic) or phenotype II (protumori-
genic). TNF-𝛼 and lipopolysaccharide (LPS) have been pro-
posed to be inducers of phenotype I, while phenotype II
could be induced by CXCL14, hedgehog (Hh), or TGF-𝛽
[66]. Also, similar polarization has been suggested for MSC
population [51, 81]. Complexity of determination of TAF as
individual phenotype has been nicely described by Xiong
et al., 2015 [82], where the author has proposed that TAFs
could be generated at various points in intertwined cascades
of mesenchymal and hematopoietic stem cells differentiation
[83–85].
6. MSCs as Regulators of Inflammation
Evidences about potential of MSCs to suppress immune
response due to direct or paracrine communication with
immune cells are described elsewhere [49]. After establishing
their immunomodulatory potential in vitro and in vivo,
bone marrow MSCs have been introduced into the clinical
settings, in which these cells showed their therapeutic effects
in treatment of acute grade IV GvHD after bone marrow
transplantation [86]. However, as in case of immune cells,
immunosuppressive potential of MSCs is context-dependent
[38]. As mentioned above, the existence of two functional
phenotypes of MSCs, M1 (proinflammatory) and M2 (anti-
inflammatory), has been proposed [81, 87], which is similar as
in population of macrophages, thus implying the possibility
of immune cell-like behavior of MSCs [38]. As sensors of
inflammation, MSCs respond to various microenvironment
stimuli, by changing or adjusting their secretory reper-
toire and immune activity. Therefore, presence of various
cytokines in inflammatory TME, such as TNF-𝛼, interferon
(IFN)-𝛾, IL-6, IL-1, and TGF-𝛽, can govern immune activities
of MSCs [43]. Also, it has been described that MSCs can
alter activation of NF-𝜅B in macrophages thus controlling
their polarization towardM1 orM2phenotype [87]. Similarly,
it has been found that lung tumor cell factors can induce
proinflammatory phenotype inMSCs by activation of NF-𝜅B
[88], which is known to induce production of inflammatory
factors with tumor-supporting roles such as IL-6, TGF-𝛽,
and IL-1 [89]. Thus, it seems that MSCs can behave like
immune cells, responding to inflammatory factors of TME
and modifying their secretory and activity profile to more
immunosuppressive.
7. IL-6
Contribution of MSCs to tumor development is highly
dependent on IL-6 activities. It is well known that IL-6 in joint
action with hypoxia supports immune evasion of tumor cells,
polarizing macrophages to suppressive M2 phenotype [90]
and promotingTh17 immune response [91]. It has been found
that senescent umbilical cord MSCs produce high amount
of IL-6, which is shown to be major mediator of MSCs and
tumor cells crosstalk [92]. IL-6 secreted fromMSCs activates
STAT3 phosphorylation in breast tumor cells, stimulating
their proliferation and migration [93]. Moreover, it has been
demonstrated that tumor cells and especially their secreted
molecules or extracellular vesicles induce higher expression
of IL-6 in MSCs, thus educating them to acquire tumor-
supporting properties [94]. Also, it has been shown that
CD90+ cells in TME, assigned as MSC-derived TAFs, are
major source of IL-6 in colorectal cancers. Besides, IL-6 has
been shown to induce expansion of cancer stem-like cells in
tumors, as well as Th17 immune response, thus stimulating
tumor progression [95]. As has been shown that expression
of IL-6 by MSCs is dependent on their differentiation stage,
it could be speculated that TME can regulate expression
and production of IL-6 in MSCs affecting their stem-like
features. It has been proposed that IL-6 produced by TAFs
leads to inhibition of monocyte and macrophage differentia-
tion and function, contributing to final immunosuppression
and creation of tumor-promoting microenvironment [96].
Additionally, it has been reported that presence of IL-6, as
well as TNF-𝛼 and IL-1, can lead to neoplastic transformation,
through activation of the NF𝜅B and increment of cyclin D1 in
normal cells, thus connecting tumorigenesis with inflamma-
tion [97]. As MSCs can be source of these proinflammatory
cytokines, it is plausible to speculate about contribution of
MSCs to neoplastic phenotype development. Although IL-6
has been well described as important factor in regulation of
MSCs and tumor cells properties, its mechanisms of action
in crosstalk of MSCs and tumor cells are still not completely
understood.
8. TGF-𝛽
As has been recognized as an important player during the
multistep cascade of tumor development and progression,
TGF-𝛽 is one of the most investigated immunosuppressive
cytokines in TME. However, dual role of TGF-𝛽 in tumor
development is well known. Namely, in early stages of tumor
development, TGF-𝛽 has antiproliferative effect on tumor
cells, inducing cell cycle arrest. In contrary, in later stages,
TGF-𝛽 has tumor-promoting role, activating transcriptional
factors Smad3/4 and Wnt, supporting EMT and stemness
of tumor cells [97]. As mentioned above, TGF-𝛽 plays
critical role in crosstalk of cells within TME, especially
differentiation/transdifferentiation of MSCs or fibroblasts
into activated tumor-promoting TAFs [64]. Additionally,
it has been described that TGF-𝛽 and hypoxia present in
tumor tissue can synergistic master properties of TAFs and
TAMs, favoring tumor growth [98]. It has been demon-
strated that gastric tumor cells force differentiation of MSCs
toward TAFs, through activation of TGF-𝛽/Smad2 pathway
in MSCs [99]. Moreover, it has been shown that ovarian
tumor cells can decrease activity of NK cells via TGF-𝛽,
thus contributing to evasion of antitumor immunity [100].
TGF-𝛽 is also known to be responsible for inhibition of
T lymphocytes proliferation, disabling immune system to
destroy tumor [101]. Interestingly, it has been found that
MSCs produce TGF-𝛽, which can act in an autocrinemanner,
by activating Smad3 pathway and reducing production of
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iNOS in MSCs, thus contributing to immunogenicity of
MSCs [102]. Expression of TGF-𝛽 in adipose tissue MSCs
can be stimulated by inflammatory cytokines presented in
TME, such as IFN-𝛾 and TNF-𝛼. It has been reported that
TGF-𝛽 produced by cytokine-primed adipose tissue MSCs
contribute to EMT, migration, and invasiveness of breast
cancer cells [103]. These findings indicate important role of
TGF-𝛽 not only in regulation of tumor cells behavior, but also
in determination of MSC activity in inflammatory TME.
9. IL-1
IL-1𝛼 and IL-1𝛽 can be produced by tumor as well as stromal
cells. These cytokines are involved in development of sterile
inflammation in some tumors, such as melanomas. It has
been demonstrated that IL-1𝛼/𝛽 produced by tumor cells
can augment capacity of MSCs-derived TAFs to suppress
proliferation and function of T lymphocytes. Also it has been
shown that these effects are achieved through stimulation of
COX-2 and immune-checkpoint inhibitors PD-L1 and PD-
L2 expression in MSCs-derived TAFs [104]. Moreover, it has
been demonstrated that in vitro transformation of MSCs
contributes to their immunosuppressive capacity, by causing
reduction of their immunogenicity and enhancing capacity
to suppress proliferation of T lymphocytes. Despite disrupted
IFN-𝛾 signalization, activity of IL-1𝛽 sustains immunosup-
pressive potential of transformed MSCs. Namely, in vitro
transformedMSCs possess higher expression of IL-1𝛽, which
acts as intrinsic mediator of inflammation and masters
relation of tumorigenicity and immune surveillance escape
in an autocrine manner [105]. Additionally, increment of IL-
1𝛽 in TME can lead to stabilization of HIF-1 in tumor cells
and contribute to tumorigenesis through activation of genes
implicated in metabolism, angiogenesis, and migration [98].
It has been demonstrated that IL-1𝛼 enhances production of
TGF-𝛽 in MSCs, thus contributing to immunosuppressive
functions of MSCs and promotion of prostate cancer cell
immune surveillance evasion [106].
10. Interaction of MSCs with
Immune Cells in TME
10.1. Innate Immune Cells. Interacting with compartments of
innate immunity in TME, MSCs are able to manifest both
anti-inflammatory and proinflammatory properties. How-
ever, these features and activities of MSCs are of implausible
importance for state of TME, antitumor immunity, and tumor
development.
Macrophages and neutrophils are the most abundant
population of myeloid immune cells in TME. Due to well-
known plastic nature and ability to adapt phenotype in differ-
ent environmental conditions, macrophages play important
role in normal tissue homeostasis, as well as tumorigene-
sis. Depending on external signals presented within TME,
macrophages reversibly change their profile. Importantly,
within heterogenic population of macrophages in TEM,
TAMs have been characterized according to their functional
properties and ability to enhance tumor growth, survival,
angiogenesis, and progression [107]. High levels of IL-4, GM-
CSF, and TGF𝛽 present in TME provide macrophages to
undergo transition from proinflammatory type M1 to anti-
inflammatory M2 phenotype [16]. Similar to macrophages,
MSCs are involved in steady-state tissue homeostasis and
tumorigenesis and therefore interactions of these cells have
received great attention today. It has been observed that in
response to factors produce by macrophages type M1, MSCs
acquire immunosuppressive phenotype and produce higher
levels of iNOS, monocyte chemoattractant protein-1 (MCP-
1), and IL-6 which in turn stimulate switch of macrophages
toward M2 phenotype, facilitating tumor growth [108]. Also,
it has been observed that TGF-𝛽 produced by tumor cells
[102] or soluble factors of M1 macrophages [108] can ele-
vate production of iNOS by MSCs. In both cases, MSCs
have demonstrated tumor-promoting and immunosuppres-
sive activities. In contrary, it has been shown that iNOS-
expressing MSCs can attenuate growth of fibrosarcoma cells
[109]. According to this, it has been described that iNOS
produced by stromal cells has dual role in cancer [110]. As
role of M1 and M2 macrophages is important in early and
late phase of the tumor development [47, 111], it is possible
that similar trend can occur in MSCs. Although there is no
evidence that MSCs can contribute to M1 polarization of
macrophages, presence of iNOS-expressing M1 macrophages
within TME makes speculating whether MSCs in TME can
also achieve M1 phenotype possible. Therefore, iNOS can
be considered as switch molecule of functional states of
macrophages andMSCs in TME. However, increased expres-
sion of iNOS in MSCs must be carefully studied in context
of tumor development. Taken together, these observations
nicely exemplify very perplexed collaboration of MSCs and
macrophages in TME [107].
Additionally, it has been found that mouse MSCs
derived from lymphomas induce stronger recruitment of
CD11b+Ly6C+ monocytes, F4/CD80+ macrophages, and
CD11b+Ly6G+ neutrophils toward tumor tissue in compari-
son to healthy bone marrow MSCs. However, in this study
it has been reported that lymphoma-derived MSCs pro-
mote tumor growth, expressing high levels of CCR2 ligands
which lead to accumulation of monocytes and macrophages.
Accumulation of monocytes and macrophages, but not neu-
trophils, has been essential for tumor progression. In pres-
ence of TNF-𝛼, healthy bonemarrowMSCs have been shown
to possess similar effects on monocytes and macrophages
recruitment as lymphoma-derived MSCs, thus contributing
to tumor growth.These results suggest that lymphomaMSCs
more potently support tumor growth than bone marrow
MSC, while TNF-𝛼 could induce tumor-promoting effects of
healthy bone marrow MSCs [112].
Reciprocal interactions of tumor-associated neutrophils
(TANs) andMSCs in TME are not studied in detail, although
it has been assumed that TANs can support or inhibit tumor
development. It has been previously reported that cocultiva-
tion of mouse TNF-𝛼 treated bone marrow MSCs induced
immunosuppressive functions of CD11b+Ly6G+ neutrophils.
Cocultivation with MSCs increases arginase activity and
expression of iNOS in neutrophils, promoting their capacity
to inhibit proliferation of T lymphocytes and leading to
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stimulation of tumor growth in vivo. These results indicate
that MSCs can promote immunosuppressive function of
neutrophils which contribute to tumor development [113].
Moreover, it has been observed that cooperation of TANs
and TAFs in follicular lymphoma contributes to promotion
of malignancy of lymphoma cells. Namely, it has been found
that TAFs presented in lymphoma produce high level of
IL-8 which stimulated neutrophil survival. In turn, neu-
trophils activate TAFs through NF-𝜅B activation, leading to
proinflammatory TAF phenotype generation, which increase
survival of malignant B-cells, as well as recruitment of
monocytes and neutrophils [114].
Immature cells of myeloid lineage, including monocytes,
macrophages, neutrophils, and dendritic cells, participate in
one heterogeneous population of MDSCs. Despite absence of
harmonized panel of characterization markers for MDSCs,
expansion of these cells has been detected in various tumor
tissues [115].MDSCs have been shown to inhibit proliferation
of T lymphocytes and stimulate generation of Treg, thus
contributing to immunosuppressivemilieu of TME. Recently,
it has been observed that pathological conditions of multiple
myeloma can induce altered functional profile of MSCs.
Namely, it has been described that human MSCs derived
from healthy donors can induce generation of granulocytic-
MDSCs, while only MSCs derived from multiple myeloma
patients induce expansion of granulocytic-MDSCs with
immunosuppressive capacity. Multiple myeloma MSCs have
induced expression of high levels of arginase-1, TNF-𝛼,
and angiogenic factor PROK2 in MDSCs, thus contribut-
ing to tumor development [116]. Additionally, it has been
demonstrated that human umbilical cord blood MSCs secret
the chemokines growth-regulated oncogene CXCL1, CXCL2,
and CXCL3 which affect differentiation and function of
human monocyte-derived dendritic cells. In this study, it has
been revealed that MSCs mitigate maturation of monocyte-
derived dendritic cells driving their differentiation toward
MDSCs in vitro. Namely, exposure of MDSCs to chemokines
secreted by MSCs induces their immunosuppressive pheno-
type and production of increased levels of IL-10 and IL-4
and reduced levels of proinflammatory cytokines IL-12 and
IFN-𝛾. In this study it has been demonstrated that mouse
bone marrow MSCs stimulate differentiation of mouse bone
marrow dendritic cells towardMDSC-like cells Gr-1+CD11b+
in vivo, enhancing their expression of the arginase-1 and
iNOS mRNA, which contribute to their anti-inflammatory
activity [117]. Furthermore, it has been observed that MSCs
can stimulate expansion of CD14−CD11b+CD33+ MDSCs
from peripheral blood leukocytes, by producing HGF that
binds to c-Met on MDSCs, and consequently increase phos-
phorylation of STAT3, necessary for expansion of MDSCs
[118]. In contrary, it has been observed that mouse bone
marrow MSCs inhibited generation and proliferation of Gr-
1+CD11b+MDSCs in peripheral blood and bonemarrow, and
these effects have been suggested to be related to suppression
of tumor growth in vitro and in vivo [119]. Thus, further
investigations are necessary to elucidate interactions ofMSCs
and MDCSs as well as consequences of their interplay on
tumor development.
10.2. Adaptive Immune Cells. Due to their ability to suppress
proliferation of effector T lymphocytes, potential use of
MSC in allogeneic transplantation experimental and clinical
settings has been investigated for long time [120]. As has
been noticed that coadministration ofMSCswith hematopoi-
etic stem/progenitor cells into patients with hematologic
malignancies can cause relapsed leukemia or development
of various tumors, potential use of MSCs in treatment of
graft-versus-host disease is still questionable [121]. However,
today it is clear that MSCs change not only proliferation,
but also differentiation and maturation of T lymphocytes. It
has been proposed that various soluble factors are involved
in MSC-mediated immunosuppression such as indoleamine
2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), iNOS, and
TGF-𝛽 which can reduce proliferation of T lymphocytes.
Also, it has been demonstrated that MSCs which have
been stimulated to express high level of IDO-1, promote
tumor growth in vitro and in vivo. Moreover, it has been
shown that MSCs significantly impair infiltration of CD8+
T lymphocytes in tumor tissue. These results indicate that
immunosuppressive role of MSCs in TME is at least partly
mediated by IDO-1 [122]. Also, it has been reported that
MSCs can provide immune protection to breast cancer cells.
Namely, TGF-𝛽 produced byMSCs inhibits proliferation and
functions of cytotoxicCD8 lymphocytes andCD56+NKcells,
while stimulating generation of Treg [123]. Interestingly, it has
been observed that TGF-𝛽 produced by MSCs can induce
generation of Treg from näıve T cells through Smad2 activa-
tion.These effects of MSCs contribute to prevention of colitis
(inflammation stage) and colitis-associated colorectal cancer
development (tumor stage) [124]. Also, MSCs can direct
outcome of hematologic malignancies, altering repertoire of
immune cells. In case of follicular lymphoma, it has been
demonstrated that MSCs sustain viability of follicular helper
T-cells, follicular regulatory T-cells and Treg, and generation
of follicular regulatory T-cells from follicular helper T-cells,
in IL-6-dependent manner [125].
Proliferation of malignant B cells in chronic lympho-
cytic leukemia (CLL), follicular lymphoma (FL), mucosa-
associated lymphoid tissue (MALT) lymphomas, and mul-
tiple myeloma (MM) is mainly dependent on extrinsic
stimuli from microenvironment, antigens, cytokines, and
cell-cell interactions which are proposed to be responsible
for nonefficacy of therapeutics [126]. It has been reported
that stromal cells produce cytokines IL-4 and IL-21, which
bind to interleukin receptor on lymphoma cells (IL-4R/IL-
21R) or chemokines CXCL12 and CXCL13, thus forming
the complex which is also implicated in evolution of tumor
microenvironment and moreover in acquirement of malig-
nant properties by cells [127]. There are reports emphasizing
that interactions with bone marrow MSCs are critical for
survival of malignant B cells, regulating apoptosis-regulatory
protein Bcl-2 expression.However,MSCs have been shown as
key factor of survival of normal as well as malignant B cells in
CLL and acute lymphoblastic leukemia [128]. Also, it has been
found thatMSCs produce IL-6 which stimulates proliferation
and differentiation of B cells in multiple myeloma [129]. In
case of mantle cell lymphoma, it has been demonstrated
that long term cocultivation with stromal cells contributes
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to drug-resistance of primary mantle cell lymphoma cells,
partly via NF-𝜅B activation in B cells which lead to increased
survival, migration, and drug resistance [130]. Since MSCs
regulate proliferation and differentiation of hematopoietic
stem and progenitor cells, it has been suggested that MSCs
can also sense transformedHSCs and leukemic stem cells and
regulate their expansion and disease development [131].
11. Antitumor Features of MSCs
Considering ability of MSCs to home to tumor tissue, their
use as novel tool in antitumor therapy has been suggested.
Namely, it has been shown that human umbilical cordMSCs,
previously modified for high expression of IL-18 gene, inhibit
proliferation and invasiveness of breast cancer cells. It has
been proposed that MSCs expressing IL-18 inhibit prolifera-
tion of breast cancer cells by alteration of their cell cycle [132].
Additionally, it has been reported that umbilical cord MSCs
with previously enhanced IL-15 gene expression significantly
suppresses pancreatic tumor growth in mice. Moreover, in
this study it has been demonstrated that MSCs, induced for
IL-15 expression, stimulate accumulation of NK cells and
CD8+ T lymphocytes, thus supporting antitumor immune
response [133]. Also, it has been shown that IFN-𝛽-producing
MSCs frombonemarrow [134], as well as adipose tissue [135],
inhibit proliferation of hepatocellular carcinoma or breast
cancer, respectively. Additionally, it has been reported that
IFN-𝛽-producing bonemarrowMSCs attenuate proliferation
of hepatocellular carcinoma cells, modifying their cell cycle,
decreasing expression of cyclin D1 and phosphorylation of
Rb via suppressed Akt and stimulated FOXO3a activity [134].
On the other side, it has been shown that IFN-𝛽-producing
adipose tissue MSCs exert cytotoxic effect on breast tumor
cells mediated by STAT1 activation [135].
Additionally, it has been shown that TNF-related apopto-
sis inducing ligand (TRAIL) can selectively trigger apoptosis
in tumor cells [136]. Similar antitumor activity of MSCs has
been observed in vivo in mouse xenograftmodel of intraperi-
toneal human mesothelioma where MSCs overexpressing
TRAIL attenuate inflammation inTME [137]. Also, antitumor
activity of MSCs expressing TRAIL has been reported in
xenograft models of sarcomas [138] and breast cancer [139].
Considering iNOS gene therapy for cancer treatment, it has
been demonstrated that human MSCs expressing iNOS can
inhibit/delay growth of fibrosarcoma in xenograft mouse
model. It is suggested that delivered iNOS can generate NO
or other cytotoxic intermediate molecules affecting viability
of tumor cells [109]. These data indicate that MSCs modified
for expression of tumor-inhibiting factors potentially may
represent new approach in targeted antitumor therapy.
12. Concluding Remarks
Maintenance of chronic inflammation in TME requires
engagement of important cellular compartments: tumor cells,
immune cells, and MSCs. The mechanisms of the interplay
between these cells are currently the subject of intensive
experimental investigation andmany questions are remained
open. Chronic inflammation associated with hypoxia in
TME provides generation of specific niche for MSCs, adjust-
ing their phenotype and immune-related properties, thus
bringing additional complexity to regulation of MSCs and
tumor cells communication. Although many studies have
reported supportive role of MSCs in tumor development,
some investigations invest efforts to utilize tumor-homing
capacity of MSCs to mitigate inflammation in TME or
stimulate antitumor immune response.
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6 originated from breast cancer tissue-derived mesenchymal
stromal cells may contribute to carcinogenesis,” Tumor Biology,
vol. 36, no. 7, pp. 5667–5677, 2015.
[93] G.-H. Di, Y. Liu, Y. Lu, J. Liu, C. Wu, and H.-F. Duan, “IL-6
secreted from senescent mesenchymal stem cells promotes
proliferation and migration of breast cancer cells,” PLoS ONE,
vol. 9, no. 11, Article ID e113572, 2014.
[94] H.Haga, I. K. Yan,K. Takahashi, J.Wood,A. Zubair, andT. Patel,
“Tumour cell–derived extracellular vesicles interact with mes-
enchymal stem cells to modulate the microenvironment and
enhance cholangiocarcinoma growth,” Journal of Extracellular
Vesicles, vol. 4, Article ID 24900, 2015.
[95] P. T. Huynh, E. J. Beswick, Y. A. Coronado et al., “CD90+
stromal cells are the major source of IL-6, which supports
cancer stem-like cells and inflammation in colorectal cancer,”
International Journal of Cancer, vol. 138, no. 8, pp. 1971–1981,
2016.
[96] K. De Veirman, L. Rao, E. De Bruyne et al., “Cancer associated
fibroblasts and tumor growth: focus on multiple myeloma,”
Cancers, vol. 6, no. 3, pp. 1363–1381, 2014.
[97] M. Esquivel-Velázquez, P.Ostoa-Saloma,M. I. Palacios-Arreola,
K. E. Nava-Castro, J. I. Castro, and J. Morales-Montor, “The role
of cytokines in breast cancer development and progression,”
Journal of Interferon and Cytokine Research, vol. 35, no. 1, pp.
1–16, 2015.
[98] C. S. Curran and P. J. Keely, “Breast tumor and stromal cell
responses to TGF-𝛽 and hypoxia in matrix deposition,”Matrix
Biology, vol. 32, no. 2, pp. 95–105, 2013.
[99] J. Gu, H. Qian, L. Shen et al., “Gastric cancer exosomes trigger
differentiation of umbilical cord derived mesenchymal stem
cells to carcinoma-associated fibroblasts through TGF-𝛽/Smad
pathway,” PLoS ONE, vol. 7, no. 12, Article ID e52465, 2012.
[100] E. B. Wilson, J. J. El-Jawhari, A. L. Neilson et al., “Human
tumour immune evasion via TGF-𝛽 blocks NK cell activation
but not survival allowing therapeutic restoration of anti-tumour
activity,” PLoS ONE, vol. 6, no. 9, Article ID e22842, 2011.
[101] D. A. Thomas and J. Massagué, “TGF-𝛽 directly targets
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